Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Relay Therapeutics Inc (NASDAQ: RLAY) closed at $8.18 down -3.31% from its previous closing price of $8.46. In other words, the price has decreased by -$3.31 from its previous closing price. On the day, 1.57 million shares were traded. RLAY stock price reached its highest trading level at $8.5487 during the session, while it also had its lowest trading level at $8.06.
Ratios:
For a deeper understanding of Relay Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.14 and its Current Ratio is at 19.14. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $4.Wells Fargo initiated its Equal Weight rating on April 17, 2025, with a $4 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 03 ’25 when Patel Sanjiv sold 62,073 shares for $7.00 per share. The transaction valued at 434,511 led to the insider holds 703,215 shares of the business.
Rahmer Peter sold 21,394 shares of RLAY for $160,455 on Oct 29 ’25. The insider now owns 337,469 shares after completing the transaction at $7.50 per share. On Oct 28 ’25, another insider, Rahmer Peter, who serves as the insider of the company, sold 19,135 shares for $7.29 each. As a result, the insider received 139,494 and left with 358,863 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 1417777152 and an Enterprise Value of 854675136. For the stock, the TTM Price-to-Sale (P/S) ratio is 169.59 while its Price-to-Book (P/B) ratio in mrq is 2.32. Its current Enterprise Value per Revenue stands at 102.295 whereas that against EBITDA is -2.667.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.55, which has changed by 0.7899344 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $9.04, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is 9.96%, while the 200-Day Moving Average is calculated to be 77.78%.
Shares Statistics:
For the past three months, RLAY has traded an average of 2.13M shares per day and 2193400 over the past ten days. A total of 172.63M shares are outstanding, with a floating share count of 130.41M. Insiders hold about 24.76% of the company’s shares, while institutions hold 74.69% stake in the company. Shares short for RLAY as of 1765756800 were 20296216 with a Short Ratio of 9.53, compared to 1763078400 on 21371170. Therefore, it implies a Short% of Shares Outstanding of 20296216 and a Short% of Float of 14.19.
Earnings Estimates
The stock of Relay Therapeutics Inc (RLAY) is currently in the spotlight, with 7.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.41 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.5 and -$2.08 for the fiscal current year, implying an average EPS of -$1.74. EPS for the following year is -$1.61, with 6.0 analysts recommending between -$1.41 and -$1.78.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for RLAY’s current fiscal year. The highest revenue estimate was $38.4M, while the lowest revenue estimate was $8M, resulting in an average revenue estimate of $12.77M. In the same quarter a year ago, actual revenue was $10.01M
